Acrivon Therapeutics, Inc.

ACRV · NASDAQ

Acrivon has an AP3-guided oncology platform, a lead ACR-368 endometrial-cancer catalyst, and cash runway into Q3 2027, but it is still pre-revenue and dependent on clinical data, diagnostics, and future financing.

Follow Add to Watchlist Ask Question

NASDAQ ACRV Coverage Bootstrap Health Care Biotechnology Precision Oncology

Latest ReportMay 13, 2026Acrivon Therapeutics: the cancer-data story with a 2026 readout clockView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.